Karyopharm Therapeutics Inc.
selinexor
myelofibrosis
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews selinexor for myelofibrosis around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The Company will be meeting with the U.S. Food and Drug Administration (FDA) to discuss the totality of the data from the SENTRY trial and its supplemental new drug application (sNDA) filing plan.”